AN 2718

Drug Profile

AN 2718

Alternative Names: AN-2718

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Antifungals; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Candidiasis; Mycoses; Onychomycosis; Tinea

Most Recent Events

  • 13 Oct 2015 Discontinued - Phase-I for Tinea, Onychomycosis and Mycoses in USA before October 2015 (Topical)
  • 21 Mar 2013 AN 2718 is still in phase I development for Onychomyosis and other Mycoses in USA
  • 05 Mar 2009 Adverse events data from a phase I trial in Tinea released by Anacor Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top